Concurrent chemoradiotherapy with nedaplatin in patients with stage IIA to IVA cervical carcinoma

Fujioka,Toru; Yasuoka,Toshiaki; Koizumi,Masae; Tanaka,Hiroki; Hashimoto,Hisashi; Nabeta,Motoo; Koizumi,Koji; Matsubara,Yuko; Hamada,Katsuyuki; Matsubara,Keiichi; Katayama,Tomihiro; Nawa,Akihiro

doi:10.3892/mco.2012.27

Concurrent chemoradiotherapy with nedaplatin in patients with stage IIA to IVA cervical carcinoma

Authors:
- Toru Fujioka
- Toshiaki Yasuoka
- Masae Koizumi
- Hiroki Tanaka
- Hisashi Hashimoto
- Motoo Nabeta
- Koji Koizumi
- Yuko Matsubara
- Katsuyuki Hamada
- Keiichi Matsubara
- Tomihiro Katayama
- Akihiro Nawa
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Ehime University, Graduate School of Medicine, Ehime, Japan
Published online on: September 25, 2012 https://doi.org/10.3892/mco.2012.27
Pages: 165-170

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to evaluate the efficacy and toxicities of nadaplatin‑based concurrent chemoradiotherapy (CCRT) in patients with stage IIA to IVA cervical carcinoma. Patients with an International Federation of Gynecology and Obstetrics (FIGO) stage IIA to IVA cervical carcinoma were treated with nadaplatin‑based CCRT, using high‑dose rate intracavitary brachytherapy (HDR-ICBT) or radiotherapy (RT) alone, in patients with FIGO stage IIA to IVA cervical carcinoma. CCRT with nedaplatin (80 mg/m2) was administered on Days 1 and 29. The records of 17 women treated either with nadaplatin‑based CCRT using HSR-ICBT (n=8) or RT alone (n=9), for stage IIA to IVA cervical carcinoma were retrospectively reviewed. The activity and toxicity were compared in the two treatment groups. Progression‑free survival (PFS) and overall survival (OS) were the main endpoints. The 5-year overall survival rates in the CCRT and RT groups were 68.6 and 77.8%, respectively. The median OS of the CCRT and RT groups was 38.5 and 27.3 months, respectively. There was no significant difference in either PFS (P=0.618) or OS (P=0.231). The most common grade 3-4 or higher toxicities in the CCRT groups were leuko‑/neutropenia (37.5%). The frequency of acute grade 3‑4 toxicity was higher in the CCRT compared to the RT group. However, no statistically significant difference was observed. Nedaplatin-based CCRT was safely performed. Although the prognosis of patients with FIGO stage IIA to IVA cervical carcinoma was not significantly improved, fewer distant relapses were observed in this treatment. Consequently, nedaplatin-based CCRT may be considered as a potential alternative to cisplatin‑based CCRT in this patient population.

View Figures

View References

1.	Goonatillake S, Khong R and Hoskin P: Chemoradiation in gynaecological cancer. Clin Oncol (R Coll Radiol). 21:566–572. 2009.
2.	Pearcey R, Brundage M, Drouin P, et al: Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. 20:966–972. 2002.
3.	Tzioras S, Pavlidis N, Paraskevaidis E and Ioannidis JP: Effects of different chemotherapy regimens on survival for advanced cervical cancer: systematic review and meta-analysis. Cancer Treat Rev. 33:24–38. 2007.
4.	Keys HM, Bundy BN, Stehman FB, et al: Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 340:1154–1161. 1999.
5.	Morris M, Eifel PJ, Lu J, et al: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 340:1137–1143. 1999.
6.	Rose PG, Bundy BN, Watkins EB, et al: Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 340:1144–1153. 1999.
7.	Whitney CW, Sause W, Bundy BN, et al: Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB–IVA carcinoma of the cervix with negative para-aortic lymph nodes: a gynecologic oncology group and southwest oncology group study. J Clin Oncol. 17:1339–1348. 1999.
8.	Peters WA III, Liu PY, Barrett RJ II, et al: Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 18:1606–1613. 2000.
9.	Fukuda M, Shinkai T, Eguchi K, et al: Phase II study of (glycolate-O,O′) diammineplatinum(II), a novel platinum complex, in the treatment of non-small cell lung cancer. Cancer Chemother Pharmacol. 26:393–396. 1990.
10.	Inuyama Y, Miyake H, Horiuchi M, Hayasaki K, Komiyama S and Ota K: [A late phase II clinical study of cis-diammine glycolato platinum, 254-S, for head and neck cancers]. Gan To Kagaku Ryoho. 19:871–877. 1992.
11.	Kato T, Nishimura H, Yakushiji M, et al: [Phase II study of 254-S (cis-diammine glycolato platinum) for gynecological cancer]. Gan To Kagaku Ryoho. 19:695–701. 1992.
12.	Uehara T, Watanabe H, Itoh F, et al: Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats. Arch Toxicol. 79:451–460. 2005.
13.	Kawai Y, Taniuchi S, Okahara S, Nakamura M and Gemba M: Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation. Biol Pharm Bull. 28:1385–1388. 2005.
14.	Kameyama Y, Okazaki N, Nakagawa M, Koshida H, Nakamura M and Gemba M: Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney cortical slices. Toxicol Lett. 52:15–24. 1990.
15.	Sasaki Y, Amano T, Morita M, et al: Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion. Cancer Res. 51:1472–1477. 1991.
16.	Nakamura Y, Hasegawa M, Hayakawa K, et al: Induction of p53-dependent apoptosis in vivo by nedaplatin and ionizing radiation. Oncol Rep. 7:261–265. 2000.
17.	Tanaka T, Yukawa K and Umesaki N: Radiation reduces carboplatin sensitivity and enhances nedaplatin sensitivity in cervical squamous cell carcinoma in vitro. Eur J Gynaecol Oncol. 28:352–355. 2007.
18.	Hatae M, Takahashi T, Kodama S, et al: [A dose escalation study of concurrent chemoradiation therapy with nedaplatin for cervical cancer]. Gan To Kagaku Ryoho. 32:473–478. 2005.
19.	Ota K, Wakui A, Majima H, et al: [Phase I study of a new platinum complex 254-S, cis-diammine (glycolato)-platinum (II)]. Gan To Kagaku Ryoho. 19:855–861. 1992.
20.	Mabuchi S, Ugaki H, Isohashi F, et al: Concurrent weekly nedaplatin, external beam radiotherapy and high-dose-rate brachytherapy in patients with FIGO stage IIIb cervical cancer: a comparison with a cohort treated by radiotherapy alone. Gynecol Obstet Invest. 69:224–232. 2010.
21.	Yokoyama Y, Takano T, Nakahara K, et al: A phase II multicenter trial of concurrent chemoradiotherapy with weekly nedaplatin in advanced uterine cervical carcinoma: Tohoku Gynecologic Cancer Unit Study. Oncol Rep. 19:1551–1556. 2008.
22.	Niibe Y, Tsunoda S, Jobo T, et al: Phase II study of radiation therapy combined with weekly nedaplatin in locally advanced uterine cervical carcinoma (LAUCC): kitasato gynecologic radiation oncology group (KGROG 0501)-initial analysis. Eur J Gynaecol Oncol. 29:222–224. 2008.